

## **REMARKS**

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

### **Amendments to Specification and Abstract**

The specification and abstract have been amended to replace “sugar ester fatty acid” with “sucrose ester fatty acid”, which is the appropriate term based on the original Japanese PCT application, upon which this application is based. Support for this amendment is also found in the Japanese priority application. A Substitute Specification and Abstract are attached. No new matter has been added to the application by this typographical correction.

### **Claim Amendments**

Claim 1 has been amended to clarify that cefditoren pivoxil is present in the solid dispersion composition, and to incorporate the limitation from claim 2 regarding the range of sucrose ester fatty acid.

Claims 10 and 11 have been amended in a similar manner.

Claim 2 has been amended to include the phrase “on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil”, in order to be consistent with claim 1.

The phrase “0.1 to 200 mg of the sucrose ester fatty acid and” has been deleted from claim 5, as this language is now recited in independent claim 1.

Claims 2 and 4 have been amended to delete the “preferably” language.

Claims 6, 8, 10 and 11 have been amended in order to provide proper antecedent basis for the claim limitations.

The claims have also been amended to replace “sugar ester fatty acid” with “sucrose ester fatty acid”, which is the appropriate term based on the original Japanese PCT application, and the Japanese priority application for this application.

No new matter has been added to the application by the above-discussed amendments.

**Rejection Under 35 U.S.C. § 112, First Paragraph**

The rejection of claims 1-11 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement, is respectfully traversed for the following reasons.

The Examiner asserts that the amount of the various ingredients present in the composition is related to the efficacy of 100 mg of the drug cefditoren pivoxil. The Examiner takes the position that no indication is given in the specification as to how one determines the efficacy of 100 mg of cefditoren pivoxil so that one knows the basis on which the amount of other ingredients present is computed.

Applicants respectfully disagree with the Examiner's position for the following reasons.

"Efficacy" (potency) is a unit of an effective amount of antibiotics. Specifically, the "efficacy" is a unit commonly used for expressing an amount of an active moiety of an antibiotic. For example, when a certain antibiotic is provided as a salt, an amount of its salt-free form is expressed for an effective amount of the antibiotic.

Since cefditoren pivoxil is provided as an ester form, an amount of its ester-free form is expressed for an effective amount of cefditoren pivoxil.

For evidence, attached hereto are the relevant pages of the Japanese Pharmacopoeia Fifteenth Edition (English version), which indicates that the potency (efficacy) of cefditoren pivoxil is expressed as mass (potency) of cefditoren.

Further, also attached hereto is the notification by the Ministry of Health, Labour and Welfare in Japan, which indicates that the name and standards for the drugs concerned officially conform to those set forth in the Japanese Pharmacopoeia Fifteenth Edition.

MPEP 2163 (II)(A)(2) states that "[t]he analysis of whether the specification complies with the written description requirement calls for the examiner to compare the scope of the claim with the scope of the description to determine whether applicant has demonstrated possession of the claimed invention. Such a review is conducted from the standpoint of one of skill in the art at the time the application was filed (see, e.g., *Wang Labs. v. Toshiba Corp.*, 993 F.2d 858, 865, 26 USPQ2d 1767, 1774 (Fed. Cir. 1993)) and should include a determination of the field of the invention and the level of skill and knowledge in the art . . . Information which is well known in the art need not be described in detail in the specification. See, e.g., *Hybritech, Inc. v.*

*Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1379-80, 231 USPQ 81, 90 (Fed. Cir. 1986).”  
(Emphasis added.)

As demonstrated by the discussion above, one skilled in the art would fully understand the meaning of the term “efficacy” as employed in Applicants’ claims. Thus, in accordance with the standards set forth in the MPEP, “efficacy” is sufficiently defined in the specification. One of ordinary skill in the art could determine the efficacy of 100 mg of cefditoren pivoxil so that the other ingredients can be compared based on the cefditoren pivoxil.

Therefore, the subject matter set forth in Applicants’ claims is sufficiently described in the specification, and the above rejection should be withdrawn.

**Rejections Under 35 U.S.C. § 112, Second Paragraph**

The rejection of claims 1-11 as being indefinite under 35 U.S.C. § 112, second paragraph is respectfully traversed for the reasons stated below.

The Examiner states that “if the cefditoren pivoxil need be present in the composition and the amount of the other ingredients cannot be determined, rendering the metes and bounds of the claims indefinite”. As discussed above, Applicants have amended claim 1 to clarify that cefditoren pivoxil is present in the solid dispersion composition.

Additionally, according to MPEP 2173.02, the definiteness of claim language must be analyzed, not in a vacuum, but in light of the specification, the teachings of the prior art and the interpretation which would be given to the claim by one of ordinary skill in the art. As Applicants have shown (and discussed above), “efficacy” is understood by those skilled in the art as a unit used for expressing an amount of an active moiety of an antibiotic. Thus, even if the amounts of the other ingredients are defined by absolute mass, one of ordinary skill in the art could determine the amounts of the other ingredients.

Accordingly, the above-rejection should be withdrawn.

The rejection of claims 1, 2, 4, 10 and 11 as being indefinite under 35 U.S.C. § 112, second paragraph has been rendered moot by the above-discussed amendments.

**Patentability Arguments**

The patentability of the present invention over the disclosures of the references relied upon by the Examiner in rejecting the claims will be apparent upon consideration of the following remarks.

**Double Patenting Rejection**

The provisional rejection of claims 1-5, 7 and 9 on the ground of non-statutory obviousness-type double patenting as being unpatentable over claims 1, 2, 4-9 and 12 of co-pending U.S. Application No. 10/530,046 has been overcome by the filing of a Terminal Disclaimer, together with the required fee. Applicants submit the Terminal Disclaimer for the sole purpose of expediting prosecution, and do not acquiesce to the Examiner's rejection.

**Rejections Under 35 U.S.C. § 103(a)**

**JP 60132918 (JP '918) in view of the Merck Index**

The rejection of claims 1, 2 and 8 under 35 U.S.C. § 103(a) as being unpatentable over the English abstract of JP 60132918 (JP '918) in view of the Merck Index for cefditoren is respectfully traversed.

**Position of the Examiner**

The Examiner takes the position that JP '918 discloses compositions comprising a cephalosporin antibiotic and a sucrose fatty acid ester which had improved oral absorbability, and which can be administered in solid dosage forms. The Examiner asserts that the amount of the sucrose ester fatty acid is present between 0.01 and 50% by weight when compared to the cephalosporin antibiotic. The Examiner admits that JP '918 fail to disclose the amount of these ingredients by absolute weight and does not exemplify cefditoren pivoxil as a cephalosporin antibiotic.

The Examiner asserts that cefditoren is a third generation cephalosporin and the active metabolite of the pivaloyloxymethyl ester prodrug known as cefditoren pivoxil (Merck). The Examiner asserts that cefditoren pivoxil is a functional equivalent to the cephalosporin disclosed

in JP '918. The Examiner states that if one formulated a composition with 100 mg of cefditoren pivoxil, based on the weight ratios disclosed in JP '918, the composition could contain between 0.01 and 50 mg of sucrose fatty acid ester.

The Examiner also admits that how long the cefditoren pivoxil is maintained in amorphous state when suspended in water (Applicants' claim 8) is not disclosed in the prior art.

### Applicants' Arguments

Applicants respectfully disagree with the Examiner's position for the following reasons.

As discussed above, JP '918 discloses that a combination of cephalosporin antibiotic and a sucrose fatty acid ester improves oral absorbability. However, the reference does not refer to the problem to be solved by the present invention, i.e. that cefditoren pivoxil is easily converted from an amorphous form to a crystalline form in solution. Thus, the reference clearly fails to disclose that the amorphousness of cefditoren pivoxil, which is not even disclosed by JP '918, can be prevented by adding sucrose ester fatty acid to a solid dispersion composition of cefditoren pivoxil.

Furthermore, at the time of the priority date of the present application, one of ordinary skill in the art would refrain from adding a surfactant, such as a sucrose ester fatty acid, into a medicament. At the time of the priority date of the present application, the understanding of those skilled in the art was that the addition of a surfactant into a medicament would accelerate the crystallization of an active ingredient when the medicament is dissolved in an aqueous solution. Further, when a medicament containing a surfactant is dissolved in an aqueous solution, a supersaturated solution of the active ingredient forms on the surface of the medicament. When such a supersaturated solution moves away from the medicament, a supersaturated unsolved portion would generate as a crystal.

In support of the above discussion. Applicants direct the Examiner's attention to Reference Example 2 of the specification, which demonstrates that when a surfactant other than a sugar ester fatty acid is used, (in this case, Tween 80), the crystallization of amorphous cefditoren pivoxil is accelerated. (Please see Table 3 on page 11 of Applicants' original specification for the results based on Reference Example 2, in comparison with examples which employed

sucrose ester fatty acid.)

Accordingly, at the time of the present invention, one skilled in the art would not have combined the teachings of the references in the manner suggested by the Examiner.

For these reasons, the subject matter of the above-rejected claims is clearly patentable over the cited combination of references.

Kikkoji et al. (EP 0629404) in view of JP 60132918 (JP '918)

The rejection of claims 1, 3-7 and 9-11 under 35 U.S.C. § 103(a) as being unpatentable over Kikkoji et al. (EP 0629404) in view of the English abstract of JP 60132918 (JP '918) is respectfully traversed.

Position of the Examiner

The Examiner takes the position that Kikkoji et al. disclose pharmaceutical compositions for oral administration of cefditoren pivoxil and hydroxypropylcellulose. The Examiner admits that Kikkoji et al. fail to teach the inclusion of a sugar fatty acid ester, as well as a liquid composition in which the solid composition is dissolved or suspended in a liquid.

The Examiner relies upon JP '918 for the reasons previously stated. The Examiner states that it would have been obvious to one of ordinary skill in the art at the time of Applicants' invention to combine the teachings of Kikkoji et al. and JP '918.

Applicants' Arguments

Applicants respectfully disagree with the Examiner's position for the following reasons.

EP '404 discloses the use of hydroxypropylcellulose in cefditoren pivoxil compositions. However, EP '404 does not refer to the problem to be solved by the present invention, i.e. that cefditoren pivoxil is easily converted from an amorphous form to a crystalline form in a solution, nor does it disclose that the amorphousness of cefditoren pivoxil can be prevented by adding sugar ester fatty acid to a solid dispersion composition of cefditoren pivoxil.

Additionally, for the reasons discussed above, at the time of the priority date of the present application, one of ordinary skill in the art would have refrained from adding a surfactant,

such as a sugar ester fatty acid, into a medicament. Thus, at the time of the present invention, one skilled in the art would not have combined the teachings of the references in the manner suggested by the Examiner.

For these reasons, the subject matter of the above-rejected claims is clearly patentable over the cited combination of references.

**Conclusion**

Therefore, in view of the foregoing amendments and remarks, it is submitted that each of the grounds of rejection set forth by the Examiner has been overcome, and that the application is in condition for allowance. Such allowance is solicited.

If, after reviewing this Amendment, the Examiner feels there are any issues remaining which must be resolved before the application can be passed to issue, the Examiner is respectfully requested to contact the undersigned by telephone in order to resolve such issues.

Respectfully submitted,

Shigeru CHIKASE et al.

By: 

Amy E. Schmid  
Registration No. 55,965  
Attorney for Applicants

AES/emj/jmj  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 14, 2008

Attachments: Substitute Specification (marked up version)  
Substitute Specification (clean version)

**Operating conditions—**

Proceed as directed in the Assay under Cefdinir.

**System suitability—**

**System performance:** When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of cefdinir are not less than 2000 and not more than 2.0, respectively.

**System repeatability:** When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of cefdinir is not more than 1.0%.

**Particle size <6.03>** It meets the requirement of fine granules of the Powders.

**Assay** Powder, if necessary, and weigh accurately an amount of Cefdinir Fine Granules, equivalent to about 0.1 g (potency) of Cefdinir according to the labeled amount, add 70 mL of 0.1 mol/L phosphate buffer solution, pH 7.0, shake for 30 minutes, and add 0.1 mol/L phosphate buffer solution, pH 7.0 to make exactly 100 mL. Centrifuge at 3000 revolutions per minute for 10 minutes, pipet 4 mL of the supernatant liquid, add 0.1 mol/L phosphate buffer solution, pH 7.0 to make 20 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Cefdinir Reference Standard, equivalent to about 20 mg (potency), dissolve in 0.1 mol/L phosphate buffer solution, pH 7.0 to make exactly 100 mL, and use this solution as the standard solution. Proceed as directed in the Assay under Cefdinir.

$$\text{Amount [mg (potency)] of cefdinir (C}_{14}\text{H}_{13}\text{N}_5\text{O}_5\text{S}_2) \\ = W_s \times (A_T/A_S) \times 5$$


$W_s$ : Amount [mg (potency)] of Cefdinir Reference Standard

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

**Cefditoren Pivoxil**

セフジトレン ピボキシル



$\text{C}_{25}\text{H}_{28}\text{N}_6\text{O}_7\text{S}_3$ : 620.72

2,2-Dimethylpropanoyloxymethyl (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl-amino]-3-[(1Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate [117467-28-4]

Cefditoren Pivoxil contains not less than 770  $\mu$ g (potency) and not more than 820  $\mu$ g (potency) per mg, calculated on the anhydrous basis. The potency of Cefditoren Pivoxil is expressed as mass (potency) of cefditoren ( $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_3$ : 506.58).

**Description** Cefditoren Pivoxil occurs as a light yellowish white to light yellow crystalline powder.

It is sparingly soluble in methanol, slightly soluble in acetonitrile and in ethanol (95), very slightly soluble in diethylether and practically insoluble in water.

It dissolves in dilute hydrochloric acid.

**Identification** (1) Dissolve 5 mg of Cefditoren Pivoxil in 3 mL of hydroxylammonium chloride-ethanol TS, allow to stand for 5 minutes, add 1 mL of acidic ammonium iron (III) sulfate TS and shake: a red-brown color develops.

(2) Dissolve 1 mg of Cefditoren Pivoxil in 1 mL of dilute hydrochloric acid and 4 mL of water, add 3 drops of sodium nitrite TS under ice-cooling, shake, and allow to stand for 2 minutes. Then add 1 mL of ammonium amidosulfate TS, shake well, and allow to stand for 1 minute, and add 1 mL of *N,N*-diethyl-*N'*-1-naphthylethylenediamine oxalate TS: a purple color develops.

(3) Determine the absorption spectrum of a solution of Cefditoren Pivoxil in methanol (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Cefditoren Pivoxil Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(4) Determine the spectrum of a solution of Cefditoren Pivoxil in deuterated chloroform for nuclear magnetic resonance spectroscopy (1 in 50), using tetramethylsilane for nuclear magnetic resonance spectroscopy as an internal reference compound, as directed under Nuclear Magnetic Resonance Spectroscopy <2.21> ( $^1\text{H}$ ): it exhibits single signals A, B and C, at around  $\delta$  1.1 ppm, at around  $\delta$  2.4 ppm and at around  $\delta$  4.0 ppm, double signals D and E, at around  $\delta$  6.4 ppm and at around  $\delta$  6.7 ppm, and a single signal F at around  $\delta$  8.6 ppm. The ratio of integrated intensity of each signal A:B:C:D:E:F, is about 9:3:3:1:1:1.

**Absorbance** <2.24>  $E_{1\text{cm}}^{1\%}$  (231 nm): 340 – 360 (50 mg, methanol, 2500 mL).

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : –45 – –52° (50 mg, methanol, 10 mL, 100 mm).

**Purity** (1) Heavy metals <1.07>—Proceed with 2.0 g of Cefditoren Pivoxil according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Being specified separately.

(3) Residual solvents—Being specified separately.

**Water** <2.48> Not more than 1.5% (0.5 g, volumetric titration, direct titration).

**Residue on ignition** Being specified separately.

**Assay** Conduct this procedure without exposure to daylight, using light-resistant vessels. Weigh accurately an amount of Cefditoren Pivoxil and Cefditoren Pivoxil Reference Standard, equivalent to about 40 mg (potency), dissolve in 40 mL of acetonitrile, add exactly 10 mL each of the internal standard solution, and add acetonitrile to make 100 mL, and use these solutions as the sample solution and standard solution. Perform the test with 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions,

and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of cefditoren pivoxil to that of the internal standard.

$$\text{Amount } [\mu\text{g (potency)}] \text{ of cefditoren (C}_{19}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_3) \\ = W_S \times (Q_T/Q_S) \times 1000$$

$W_S$ : Amount [mg (potency)] of Cefditoren Pivoxil Reference Standard

**Internal standard solution**—A solution of propyl *p*-hydroxybenzoate in acetonitrile (1 in 200).

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 230 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature**: A constant temperature of about 25°C.

**Mobile phase**: Dissolve 1.58 g of ammonium formate in 900 mL of water, adjust to pH 6.0 with diluted formic acid (1 in 250), and add water to make 1000 mL. To 450 mL of this solution add 275 mL of acetonitrile and 275 mL of methanol.

**Flow rate**: Adjust the flow rate so that the retention time of cefditoren pivoxil is about 15 minutes.

**System suitability**—

**System performance**: When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the internal standard and cefditoren pivoxil are eluted in this order with the resolution between these peaks being not less than 5.

**System repeatability**: When the test is repeated 5 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratios of the peak area of cefditoren pivoxil to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

## Cefditoren Pivoxil Fine Granules

セフジトレン ピボキシル細粒

Cefditoren Pivoxil Fine Granules contain not less than 90.0% and not more than 110.0% of the labeled amount of cefditoren ( $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_3$ ; 506.58).

**Method of preparation** Prepare in the form of very fine granules as directed under Powders, with Cefditoren Pivoxil.

**Identification** To an amount of powdered Cefditoren Pivoxil Fine Granules, equivalent to 0.1 g (potency) of Cefditoren Pivoxil according to the labeled amount, add 10 mL of acetonitrile, shake vigorously, and filter. To 1 mL of the filtrate add acetonitrile to make 50 mL. To 1 mL of this solution add acetonitrile to make 20 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 230 nm and 234 nm.

**Purity** Related substances—Being specified separately.

**Loss on drying** <2.41> Not more than 4.5% (0.5 g, reduced

pressure not exceeding 0.67 kPa, 60°C, 3 hours).

**Uniformity of dosage units** <6.02> The granules in single-unit container meet the requirement of the Mass variation test.

**Dissolution** Being specified separately.

**Particle size** <6.03> It meets the requirement of fine granules of the Powders.

**Assay** Conduct this procedure without exposure to daylight, using light-resistant vessels. Weigh accurately an amount of powdered Cefditoren Pivoxil Fine Granules, equivalent to about 40 mg (potency) of Cefditoren Pivoxil according to the labeled amount, add 70 mL of diluted acetonitrile (3 in 4), and shake vigorously. To this solution add exactly 10 mL of the internal standard solution, then add acetonitrile to make 100 mL, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 20 mg (potency) of Cefditoren Pivoxil Reference Standard, dissolve in 20 mL of acetonitrile, add exactly 5 mL of the internal standard solution, then add acetonitrile to make 50 mL, and use this solution as the standard solution. Proceed as directed in the Assay under Cefditoren Pivoxil.

$$\text{Amount [mg (potency)] of cefditoren (C}_{19}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_3) \\ = W_S \times (Q_T/Q_S) \times 2$$

$W_S$ : Amount [mg (potency)] of Cefditoren Pivoxil Reference Standard

**Internal standard solution**—A solution of propyl parahydroxybenzoate in acetonitrile (1 in 200)

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

## Cefditoren Pivoxil Tablets

セフジトレン ピボキシル錠

Cefditoren Pivoxil Tablets contain not less than 90.0% and not more than 110.0% of the labeled amount of cefditoren ( $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_3$ ; 506.58),

**Method of preparation** Prepare as directed under Tablets, with Cefditoren Pivoxil.

**Identification** To an amount of powdered Cefditoren Pivoxil Tablets, equivalent to 35 mg (potency) of Cefditoren Pivoxil according to the labeled amount, add 100 mL of methanol, shake, and filter. To 5 mL of the filtrate add methanol to make 100 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 229 nm and 233 nm.

**Purity** Related substances—Being specified separately.

**Loss on drying** <2.41> Not more than 4.0% (0.5 g, reduced pressure not exceeding 0.67 kPa, 60°C, 3 hours).

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Cefditoren Pivoxil Tablets add 12.5 mL of the 1st fluid for disintegration test, shake vigorously, add

# INDEX

## A

Absorptive Ointment, 265  
 Acacia, 1251  
 Acebutolol Hydrochloride, 265  
 Aceglutamide Aluminum, 266  
 Acetaminophen, 267  
 Acetazolamide, 268  
 Acetic Acid, 268  
 Acetohexamide, 269  
 Acetylcholine Chloride for Injection, 271  
 Acetylsalicylic Acid, 318  
   Tablets, 319  
 Achyranthes Root, 1252  
 Aclarubicin Hydrochloride, 272  
 Acrinol  
   and Zinc Oxide Oil, 273  
   and Zinc Oxide Ointment, 274  
   Hydrate, 274  
 Actinomycin D, 275  
 Adrenaline, 276  
   Injection, 276  
   Solution, 277  
 Adsorbed  
   Diphtheria Toxoid for Adult Use, 596  
   Diphtheria-Purified Pertussis-Tetanus Combined Vaccine, 596  
   Diphtheria-Tetanus Combined Toxoid, 596  
   Habu-venom Toxoid, 716  
   Hepatitis B Vaccine, 716  
   Purified Pertussis Vaccine, 980  
   Tetanus Toxoid, 1156  
 Agar, 1252  
 Ajmaline, 278  
   Tablets, 279  
 Akebia Stem, 1253  
 Alacepril, 279  
   Tablets, 280  
 Albumin Tannate, 282  
 Alcohol, 638  
   for Disinfection, 640  
 Aldioxa, 282  
 Alimemazine Tartrate, 283  
 Alisma Rhizome, 1253  
 Allopurinol, 284  
 Aloe, 1254  
 Alpinia Officinarum Rhizome, 1256  
 Alprazolam, 284  
 Alprenolol Hydrochloride, 285  
 Alprostadil, 286  
   Alfadex, 287  
 Alum, 292  
   Solution, 293  
 Aluminum  
   Acetylsalicylate, 319  
   Monostearate, 291  
   Potassium Sulfate Hydrate, 292  
   Sucrose Sulfate Ester, 1118  
 Amantadine Hydrochloride, 293  
 Ambenonium Chloride, 294  
 Amidotrizoic Acid, 295  
 Amikacin Sulfate, 296  
 Aminoacetic Acid, 704  
 Aminobenzylpenicillin, 307  
   Sodium, 308  
 Aminophylline  
   Hydrate, 297  
   Injection, 297  
 Amitriptyline Hydrochloride, 298  
   Tablets, 299  
 Ammonia Water, 299  
 Amobarbital, 300  
   Sodium for Injection, 300  
 Amomum Seed, 1256  
 Amorphous Insulin Zinc Injection (Aqueous Suspension), 764  
 Amoxapine, 301  
 Amoxicillin Hydrate, 302  
 Amphotericin B, 303  
   for Injection, 304  
   Syrup, 305  
   Tablets, 305  
 Ampicillin  
   Ethoxycarbonyloxyethyl Hydrochloride, 329  
   Hydrate, 307  
   Sodium, 308  
 Ampicillinphthalidyl Hydrochloride, 1138  
 Amyl Nitrite, 309  
 Anemarrhena Rhizome, 1256  
 Anesthamine, 644  
 Anesthetic Ether, 641  
 Angelica Dahurica Root, 1257  
 Anhydrous  
   Aminobenzylpenicillin, 306  
   Ampicillin, 306  
   Caffeine, 386  
   Citric Acid, 514  
   Dibasic Calcium Phosphate, 396  
   Ethanol, 639  
   Lactose, 802  
 Antipyrine, 310  
 Apricot  
   Kernel, 1257  
   Kernel Water, 1257  
 Arbekacin  
   Sulfate, 311

Sulfate Injection, 312  
 Areca, 1258  
 Arginine Hydrochloride, 313  
   Injection, 314  
 L-Arginine, 313  
   Hydrochloride, 313  
   Hydrochloride Injection, 314  
 Aromatic Castor Oil, 415  
 Arotinolol Hydrochloride, 314  
 Arsenical Paste, 315  
 Arsenic Trioxide, 316  
 Arsenous Acid, 316  
 Artemisia Capillaris Flower, 1258  
 Ascorbic Acid, 316  
   Injection, 317  
   Powder, 317  
 Asiasarum Root, 1259  
 Asparagus Tuber, 1259  
 L-Aspartic Acid, 318  
 Aspirin, 318  
   Aluminum, 319  
   Tablets, 319  
 Aspxicillin Hydrate, 320  
 Astragalus Root, 1260  
 Astromicin Sulfate, 322  
 Atenolol, 323  
 Atractylodes  
   Lancea Rhizome, 1261  
   Rhizome, 1260  
 Atropine  
   Sulfate Hydrate, 324  
   Sulfate Injection, 324  
 Azathioprine, 325  
   Tablets, 326  
 Azithromycin Hydrate, 327  
 Aztreonam, 328  
 Afloqualone, 277

## B

Bacampicillin Hydrochloride, 329  
 Bacitracin, 330  
 Baclofen, 331  
   Tablets, 332  
 Bamethan Sulfate, 333  
 Barbitol, 333  
 Barium Sulfate, 334  
 Bearberry Leaf, 1262  
 Bear Bile, 1262  
 Beclometasone Dipropionate, 335  
 Beef Tallow, 336  
 Bekanamycin Sulfate, 337  
 Belladonna  
   Extract, 1263  
   Root, 1263  
 Benidipine Hydrochloride, 338

Tablets, 339  
 Benincasa Seed, 1264  
 Benoxinate Hydrochloride, 951  
 Benserazide Hydrochloride, 340  
 Bentonite, 341  
 Benzalkonium Chloride, 342  
   Concentrated Solution 50, 343  
   Solution, 342  
 Benzbromarone, 343  
 Benzethonium Chloride, 344  
   Solution, 345  
 Benzocaine, 644  
 Benzoic Acid, 345  
 Benzoin, 1265  
 Benzyl  
   Alcohol, 346  
   Benzoate, 347  
 Benzylpenicillin  
   Benzathine Hydrate, 348  
   Potassium, 349  
 Berberine  
   Chloride Hydrate, 351  
   Tannate, 352  
 Betahistine Mesilate, 353  
   Tablets, 354  
 Betamethasone, 355  
   Dipropionate, 358  
   Sodium Phosphate, 359  
   Tablets, 356  
   Valerate, 360  
   Valerate and Gentamicin Sulfate  
     Cream, 361  
   Valerate and Gentamicin Sulfate  
     Ointment, 362  
 Bethanechol Chloride, 363  
 Bezafibrate, 364  
   Sustained Release Tablets, 365  
 Bifonazole, 366  
 Biperiden Hydrochloride, 366  
 Bisacodyl, 367  
   Suppositories, 368  
 Bismuth  
   Subgallate, 368  
   Subnitrate, 369  
 Bitter  
   Cardamon, 1265  
   Orange Peel, 1265  
   Tincture, 1266  
 Bleomycin  
   Hydrochloride, 370  
   Sulfate, 372  
 Boric Acid, 374  
 Bromazepam, 374  
 Bromhexine Hydrochloride, 375  
 Bromocriptine Mesilate, 376  
 Bromovalerylurea, 377  
 Bucillamine, 377  
 Bucumolol Hydrochloride, 378  
 Bufetolol Hydrochloride, 379  
 Bufexamac, 380  
   Cream, 380  
   Ointment, 381  
 Bumetanide, 382

Bunazosin Hydrochloride, 383  
 Bupleurum Root, 1266  
 Bupranolol Hydrochloride, 383  
 Burdock Fruit, 1267  
 Burnt Alum, 292  
 Busulfan, 384  
 Butropium Bromide, 385  
 Butyl Parahydroxybenzoate, 386

**C**

Cacao Butter, 386  
 Calciferol, 624  
 Calcium  
   Chloride Hydrate, 390  
   Chloride Injection, 390  
   Folinate, 391  
   Gluconate Hydrate, 391  
   Hydroxide, 392  
   Lactate Hydrate, 393  
   Leucovorin, 391  
   Oxide, 393  
   Pantothenate, 394  
   Paraaminosalicylate Granules, 394  
   Paraaminosalicylate Hydrate, 395  
   Polystyrene Sulfonate, 398  
   Stearate, 400  
 Calumba, 1267  
 Camellia Oil, 400  
 Camostat Mesilate, 400  
*d*-Camphor, 401  
*dl*-Camphor, 402  
 Capsicum, 1268  
   and Salicylic Acid Spirit, 1270  
   Tincture, 1269  
 Capsules, 403  
 Captopril, 403  
 Carbamazepine, 404  
 Carbazochrome Sodium Sulfonate  
   Hydrate, 405  
 Carbetapentane Citrate, 974  
 Carbetapentene Citrate, 974  
 Carbidopa Hydrate, 406  
 Carbolic Acid, 985  
   for Disinfection, 986  
 L-Carbocysteine, 407  
 Carbon Dioxide, 407  
 Carboxymethylcellulose, 408  
   Calcium, 409  
   Sodium, 410  
 Cardamon, 1271  
 Carmellose, 408  
   Calcium, 409  
   Sodium, 410  
 Carmofur, 411  
 Carnauba Wax, 411  
 Carteolol Hydrochloride, 412  
 Carumonam Sodium, 412  
 Cassia Seed, 1271  
 Castor Oil, 414  
 Catalpa Fruit, 1271  
 Caffeine  
   and Sodium Benzoate, 388  
   Hydrate, 387  
 Cefaclor, 415  
   Capsules, 416  
   Compound Granules, 419  
   Fine Granules, 417  
 Cefadroxil, 421  
 Cefalexin, 422  
 Cefalotin Sodium, 423  
 Cefapirin Sodium, 424  
 Cefatrizine Propylene Glycolate, 425  
 Cefazolin Sodium, 426  
   Hydrate, 428  
 Cefbuperazone Sodium, 429  
 Cefcapene Pivoxil Hydrochloride  
   Fine Granules, 432  
   Hydrate, 430  
   Tablets, 433  
 Cefdinir, 434  
   Capsules, 435  
   Fine Granules, 436  
 Cefditoren Pivoxil, 437  
   Fine Granules, 438  
   Tablets, 438  
 Cefepime Dihydrochloride  
   for Injection, 441  
   Hydrate, 439  
 Cefmenoxime Hydrochloride, 443  
 Cefmetazole Sodium, 445  
 Cefminox Sodium Hydrate, 446  
 Cefodizime Sodium, 447  
 Cefoperazone Sodium, 448  
 Cefotaxime Sodium, 449  
 Cefotetan, 451  
 Cefotiam  
   Hexetil Hydrochloride, 453  
   Hydrochloride, 455  
   Hydrochloride for Injection, 456  
 Cefozopran Hydrochloride, 457  
   for Injection, 458  
 Cefpiramide Sodium, 458  
 Cefpirome Sulfate, 460  
 Cefpodoxime Proxetil, 461  
 Cefroxadine Hydrate, 462  
 Cefsulodin Sodium, 464  
 Ceftazidime Hydrate, 466  
 Cefteram Pivoxil, 468  
   Fine Granules, 469  
 Ceftibuten Hydrate, 470  
 Ceftizoxime Sodium, 471  
 Ceftriaxone Sodium Hydrate, 472  
 Cefuroxime  
   Axetil, 474  
   Sodium, 476  
 Cellacefat, 480  
 Celmoleukin (Genetical Recombination), 481  
 Cetanol, 484  
 Cetraxate Hydrochloride, 485  
 Cefixime, 442  
 Chenodeoxycholic Acid, 486  
 Chloral Hydrate, 487  
 Chloramphenicol, 487  
   Palmitate, 488

## The Ministry of Health, Labour and Welfare Ministerial Notification No. 285

Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), the Japanese Pharmacopoeia (hereinafter referred to as “new Pharmacopoeia”), which has been established as follows\*, shall be applied on April 1, 2006, and the Ministry of Health, Labour and Welfare Ministerial Notification No. 111 (Matter of Establishing the Japanese Pharmacopoeia; hereinafter referred to as “previous Pharmacopoeia”), issued in 2001, shall be abolished on March 31, 2006. However, in the case of drugs which are listed in the new Pharmacopoeia (limited to those listed in the previous Pharmacopoeia) and drugs which have been approved as of April 1, 2006 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceutical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2007. In the case of drugs which are listed in the new Pharmacopoeia (excluding those listed in the previous Pharmacopoeia) and drugs which have been approved as of April 1, 2006 as prescribed under Paragraph 1, Article 14 of the same law (including those exempted from approval), they may be accepted as those being not listed in the new Pharmacopoeia before and on September 30, 2007.

**Jiro Kawasaki**

The Minister of Health, Labour and Welfare

March 31, 2006

Referring the next title to this book: “The Japanese Pharmacopoeia”.

(The text referred to by the term “as follows” are omitted here. All of them are made available for public exhibition at the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan).

\*The term “as follows” here indicates the contents of the Japanese Pharmacopoeia Fifteenth Edition from General Notices to Ultraviolet-visible Reference Spectra (pp. 1 - 1654).